Minimally invasive surgery for esophageal cancer.

Oncological and surgical outcomes of minimally invasive versus open esophagectomy for esophageal squamous cell carcinoma: a matched-pair comparative study. Int J Clin Exp Med (2015) 0.77

Case-matched analysis of combined thoracoscopic-laparoscopic versus open esophagectomy for esophageal squamous cell carcinoma. Int J Clin Exp Med (2015) 0.75

Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med (2013) 5.41

Prevalence and risk factors for ischemia, leak, and stricture of esophageal anastomosis: gastric pull-up versus colon interposition. J Am Coll Surg (2004) 2.82

Endoscopic, deep mural implantation of Enteryx for the treatment of GERD: 6-month follow-up of a multicenter trial. Am J Gastroenterol (2003) 2.63

International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). Ann Surg (2015) 2.61

Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg (2003) 2.36

Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell (2013) 2.23

Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison. Am J Gastroenterol (2006) 2.07

Endoscopic implantation of enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial. Am J Gastroenterol (2003) 1.84

Enteryx implantation for GERD: expanded multicenter trial results and interim postapproval follow-up to 24 months. Gastrointest Endosc (2005) 1.62

Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol (2012) 1.61

Esophageal function testing with combined multichannel intraluminal impedance and manometry: multicenter study in healthy volunteers. Clin Gastroenterol Hepatol (2003) 1.48

Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg (2006) 1.47

Eosinophilic esophagitis with severe GERD. Am J Gastroenterol (2009) 1.47

Atypical variants of classic achalasia are common and currently under-recognized: a study of prevalence and clinical features. J Am Coll Surg (2011) 1.41

Bile exposure inhibits expression of squamous differentiation genes in human esophageal epithelial cells. Ann Surg (2012) 1.40

Physiologic basis for the treatment of epiphrenic diverticulum. Ann Surg (2002) 1.37

Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg (2004) 1.37

Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus. Am J Gastroenterol (2002) 1.33

A new era in esophageal diagnostics: the image-based paradigm of high-resolution manometry. J Am Coll Surg (2009) 1.28

Pathogenesis of Barrett esophagus: deoxycholic acid up-regulates goblet-specific gene MUC2 in concert with CDX2 in human esophageal cells. Arch Surg (2007) 1.27

Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg (2010) 1.24

The pathogenesis of Barrett's esophagus: secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells. J Gastrointest Surg (2007) 1.21

Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. J Am Coll Surg (2013) 1.16

Esophageal perforation: surgical, endoscopic and medical management strategies. Curr Opin Gastroenterol (2010) 1.16

Hiatal hernia, lower esophageal sphincter incompetence, and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease. J Gastrointest Surg (2008) 1.15

Absence of gastroesophageal reflux disease in a majority of patients taking acid suppression medications after Nissen fundoplication. J Gastrointest Surg (2002) 1.13

The mutagenic potential of duodenoesophageal reflux. Ann Surg (2005) 1.08

En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus. Arch Surg (2004) 1.05

Preoperative lower esophageal sphincter pressure affects outcome of laparoscopic esophageal myotomy for achalasia. J Gastrointest Surg (2004) 1.02

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol (2011) 1.01

A population-based analysis of emergent vs. elective hospital admissions for an intrathoracic stomach. Surg Endosc (2009) 0.99

Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome. J Gastrointest Surg (2007) 0.99

Surgical resection for locoregional esophageal cancer is underutilized in the United States. J Am Coll Surg (2010) 0.99

Esophageal stenting for malignant and benign disease: 133 cases on a thoracic surgical service. Ann Thorac Surg (2011) 0.98

Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg (2003) 0.98

BMP-driven NRF2 activation in esophageal basal cell differentiation and eosinophilic esophagitis. J Clin Invest (2015) 0.96

Perioperative risk of laparoscopic fundoplication: safer than previously reported-analysis of the American College of Surgeons National Surgical Quality Improvement Program 2005 to 2009. J Am Coll Surg (2012) 0.95

Barrett's esophagus in females: a comparative analysis of risk factors in females and males. Am J Gastroenterol (2005) 0.95

Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma. Clin Cancer Res (2011) 0.94

Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa. Arch Surg (2005) 0.94

Update on fundoplication for the treatment of GERD. Curr Gastroenterol Rep (2012) 0.93

Achalasia of the esophagus: a surgical disease. J Am Coll Surg (2008) 0.92

Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. BMC Gastroenterol (2012) 0.90

Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch Surg (2006) 0.90

Gastrectomy as a remedial operation for failed fundoplication. J Gastrointest Surg (2007) 0.90

Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg (2002) 0.89

Association of kyphosis and spinal skeletal abnormalities with intrathoracic stomach: a link toward understanding its pathogenesis. J Am Coll Surg (2009) 0.89

The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann Thorac Surg (2004) 0.89

Physiologic mechanism and preoperative prediction of new-onset dysphagia after laparoscopic Nissen fundoplication. J Gastrointest Surg (2002) 0.89

Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR). J Gastrointest Surg (2008) 0.88

Does the value of PET-CT extend beyond pretreatment staging? An analysis of survival in surgical patients with esophageal cancer. J Gastrointest Surg (2009) 0.87

Should elective repair of intrathoracic stomach be encouraged? J Gastrointest Surg (2009) 0.87

Experimental evidence for mutagenic potential of duodenogastric juice on Barrett's esophagus. World J Surg (2003) 0.87

Improvement in educational effectiveness of morbidity and mortality conferences with structured presentation and analysis of complications. J Surg Educ (2010) 0.86

Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited. Surgery (2013) 0.85

Pathogenesis of Barrett's esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells. Surgery (2009) 0.85

Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J Gastrointest Surg (2004) 0.85

Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells. Ann Surg (2014) 0.85

Dysphagia postfundoplication: more commonly hiatal outflow resistance than poor esophageal body motility. Surgery (2012) 0.84

Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Arch Surg (2004) 0.83

Endoscopic management of early esophageal neoplasia: an emerging standard. J Gastrointest Surg (2011) 0.83

A current assessment of endoluminal approaches to the treatment of gastroesophageal reflux disease. Surg Innov (2004) 0.81

Survivin, a potential biomarker in the development of Barrett's adenocarcinoma. Surgery (2005) 0.81

Treatment strategies for esophageal cancer. Gastroenterol Clin North Am (2013) 0.81

Towards the molecular characterization of disease: comparison of molecular and histological analysis of esophageal epithelia. J Gastrointest Surg (2007) 0.81

Expression of insulin-like growth factor II mRNA-binding protein 3 in human esophageal adenocarcinoma and its precursor lesions. Arch Pathol Lab Med (2011) 0.81

Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies. BMC Gastroenterol (2014) 0.80

The management of dysplastic Barrett's esophagus: where do we go from here? Ann Surg Oncol (2002) 0.79

Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2. Int J Cancer (2006) 0.79

Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med (2013) 0.78

Laparoscopic Nissen fundoplication assessment: task analysis as a model for the development of a procedural checklist. Surg Endosc (2008) 0.78

Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol (2006) 0.78

Minimally invasive surgery for esophageal motility disorders. Surg Clin North Am (2002) 0.77

The Durability of Endoscopic Therapy for Treatment of Barrett's Metaplasia, Dysplasia, and Mucosal Cancer After Nissen Fundoplication. J Gastrointest Surg (2015) 0.77

Reflux-associated oxygen desaturations: usefulness in diagnosing reflux-related respiratory symptoms. J Gastrointest Surg (2012) 0.77

Evaluation of esophageal function for antireflux surgery. Gastrointest Endosc Clin N Am (2005) 0.76

Bile acid at low pH reduces squamous differentiation and activates EGFR signaling in esophageal squamous cells in 3-D culture. J Gastrointest Surg (2013) 0.76

The role of lymphadenectomy in the surgical treatment of esophageal and gastric cancer. Curr Probl Surg (2012) 0.76

Carcinogenesis in reflux disease--in search for bile-specific effects. Microsurgery (2007) 0.76

Getting it "just right": the continued dilemma of the ideal treatment of Barrett's esophagus with early neoplasia. Gastrointest Endosc (2008) 0.76

Excellent quality of life after Nissen fundoplication depends on successful elimination of reflux symptoms and not the invasiveness of the surgical approach. Ann Thorac Surg (2002) 0.76

Barrett's esophagus: now what? Ann Surg (2003) 0.75

Progress in outlining the frequency and risk of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc (2010) 0.75

Surgical management of hypertensive lower esophageal sphincter with dysphagia or chest pain. J Gastrointest Surg (2003) 0.75

Adenocarcinoma of the gastroesophageal junction: benefits of an extended lymphadenectomy. Surg Oncol Clin N Am (2006) 0.75

Surgical innovation and diseases of the foregut. Surg Innov (2004) 0.75

Modern surgery for esophageal cancer. Gastroenterol Clin North Am (2008) 0.75

The origins of an operation: a brief history of transhiatal esophagectomy. Ann Surg (2009) 0.75

Controversies in the current therapy of carcinoma of the esophagus. J Am Coll Surg (2002) 0.75

Letter to the editors. J Gastrointest Surg (2007) 0.75

Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease. Thorac Surg Clin (2005) 0.75

24-h multichannel intraluminal impedance-pH monitoring may be an inadequate test for detecting gastroesophageal reflux in patients with mixed typical and atypical symptoms. Surg Endosc (2014) 0.75